Your browser doesn't support javascript.
loading
SCN8A self-limited infantile epilepsy: Does epilepsy resolve?
Young, Emma; Harris, Rebekah; Lieffering, Nico; de Valles-Ibáñez, Guillem; Nyaga, Denis; Bennett, Mark F; Hildebrand, Michael S; Scheffer, Ingrid E; Sadleir, Lynette G.
Afiliación
  • Young E; Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.
  • Harris R; Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
  • Lieffering N; Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.
  • de Valles-Ibáñez G; Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.
  • Nyaga D; Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.
  • Bennett MF; Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
  • Hildebrand MS; Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
  • Scheffer IE; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia.
  • Sadleir LG; Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
Epilepsia ; 65(8): e156-e162, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38845412
ABSTRACT
SCN8A variants cause a spectrum of epilepsy phenotypes ranging from self-limited infantile epilepsy (SeLIE) to developmental and epileptic encephalopathy. SeLIE is an infantile onset focal epilepsy, occurring in developmentally normal infants, which often resolves by 3 years. Our aim was to ascertain when epilepsy resolves in SCN8A-SeLIE. We identified unpublished individuals with SCN8A-SeLIE and performed detailed phenotyping. Literature was searched for published SCN8A-SeLIE cases. Nine unpublished individuals from four families were identified (age at study = 3.5-66 years). Six had their last seizure after 3 years (range = 4-21 years); although drug-responsive and despite multiple weaning attempts (1-5), five of six remain on antiseizure medications (carbamazepine, n = 3; lamotrigine, n = 2). We identified 29 published individuals with SCN8A-SeLIE who had data on seizure progression. Of the 22 individuals aged at least 10 years, reported here or in the literature, nine of 22 (41%) had seizure offset prior to 3 years, five of 22 (23%) had seizure offset between 3 and 10 years, and eight of 22 (36%) had seizures after 10 years. Our data highlight that more than half of individuals with SCN8A-SeLIE continue to have seizures into late childhood. In contrast to SeLIE due to other etiologies, many individuals have a more persistent, albeit drug-responsive, form of epilepsy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsia / Canal de Sodio Activado por Voltaje NAV1.6 Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Epilepsia Año: 2024 Tipo del documento: Article País de afiliación: Nueva Zelanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsia / Canal de Sodio Activado por Voltaje NAV1.6 Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Epilepsia Año: 2024 Tipo del documento: Article País de afiliación: Nueva Zelanda